Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) Equity Average: 2023-2025

Historic Equity Average for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $753.3 million.

  • NewAmsterdam Pharma Co N.V's Equity Average rose 96.60% to $753.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.3 million, marking a year-over-year increase of 96.60%. This contributed to the annual value of $522.9 million for FY2024, which is 45.57% up from last year.
  • NewAmsterdam Pharma Co N.V's Equity Average amounted to $753.3 million in Q3 2025, which was down 3.17% from $777.9 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Equity Average high stood at $777.9 million for Q2 2025, and its period low was $166.1 million during Q3 2023.
  • Its 3-year average for Equity Average is $462.7 million, with a median of $399.6 million in 2024.
  • The largest annual percentage gain for NewAmsterdam Pharma Co N.V's Equity Average in the last 5 years was 130.63% (2024), contrasted with its biggest fall of 15.48% (2024).
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Equity Average stood at $310.1 million in 2023, then surged by 83.22% to $568.2 million in 2024, then spiked by 96.60% to $753.3 million in 2025.
  • Its Equity Average was $753.3 million in Q3 2025, compared to $777.9 million in Q2 2025 and $767.4 million in Q1 2025.